Futura Medical plc

Equities

FUM

GB0033278473

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:25 2024-04-26 am EDT 5-day change 1st Jan Change
35.45 GBX +0.14% Intraday chart for Futura Medical plc -0.56% +39.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Futura Medical hails results as erectile dysfunction drug drives sales AN
Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024
Futura Medical plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Futura Medical's Eroxon to soon be available on prescription AN
BP and Prudential help snap FTSE losing streak AN
Futura Medical shares surge after "transformational year" AN
Futura Medical Extends License Deal with Cooper Consumer Health MT
Futura Medical extends licensing deal for erectile dysfunction gel AN
Futura Medical plc Extends Collaboration with Cooper Consumer Health CI
Futura Medical plc Announces Appointment of Roy Davis as Non-Executive Director CI
TRADING: Zambeef sees profit above market views; Luceco trades in line AN
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Treatment in More Countries MT
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Drug in More Countries MT
Futura Medical plc Expands Partnership with M8 Pharmaceuticals, Inc CI
Futura Medical gets Mexico marketing authorisation for Eroxon gel AN
Eroxon® Granted Marketing Authorisation in Mexico CI
Futura Medical launches erectile dysfunction gel in UAE AN
UK’s Futura Medical Obtains EU Patent for Erectile Dysfunction Gel MT
Futura Medical granted European patent for ED treatment AN
Futura Medical plc Announces European Patent Office Grants Patent for Med3000 CI
Transcript : Futura Medical plc - Special Call
Elixirr record half-year revenue; Bango profit down AN
Futura Medical plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Futura Medical plc, H1 2023 Earnings Call, Sep 18, 2023
Futura Medical's ED treatment approved in Saudi Arabia AN
Chart Futura Medical plc
More charts
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3545 GBP
Average target price
1.263 GBP
Spread / Average Target
+256.37%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. FUM Stock
  4. News Futura Medical plc
  5. Futura Medical Extends License Deal with Cooper Consumer Health